# A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

> **NCT06984718** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Akeso** · enrollment: 120 (estimated)

## Conditions studied

- HCC
- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** AK104+lenvatinib
- **DRUG:** lenvatinib

## Key facts

- **NCT ID:** NCT06984718
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06984718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06984718, "A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06984718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*